Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Mauck

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Contraception|November 5, 2002
A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraceptionHe Changhai, Gui Youlun, Yang Jie, et al.
Contraception|August 21, 2007
Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 daysAnderson S Doh, Nkele Ngoh, Ron Roddy, et al.
Contraception|June 21, 2005
Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL)Kurt T Barnhart, E Scott Pretorius, Alka Shaunik, et al.
Contraception|November 16, 2004
Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 productEliana Amaral, Antero Perdigão, Maria Helena Souza, et al.
Menopause (New York, N.Y.)|August 25, 2023
A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
Menopause (New York, N.Y.)|June 20, 2023
A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
Contraception|April 22, 2006
Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 productEliana Amaral, Antero Perdigao, Maria Helena Souza, et al.
Sexually Transmitted Diseases|November 30, 2012
A quantitative glycogen assay to verify use of self-administered vaginal swabsDeborah J Anderson, Joseph A Politch, Jeffrey Pudney, et al.
Journal of Lower Genital Tract Disease|September 30, 2008
Colposcopically observed vascular changes in the cervix in relation to the hormonal levels and menstrual cycleSmita N Joshi, Soma Das, Madhuri Thakar, et al.
Contraception|May 15, 2008
Consistent use of a combination product versus a single product in a safety trial of the diaphragm and microbicide in Harare, ZimbabweAriane van der Straten, Jie Moore, Sue Napierala, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Contraception|November 5, 2002
A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraceptionHe Changhai, Gui Youlun, Yang Jie, et al.
Contraception|August 21, 2007
Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 daysAnderson S Doh, Nkele Ngoh, Ron Roddy, et al.
Contraception|June 21, 2005
Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL)Kurt T Barnhart, E Scott Pretorius, Alka Shaunik, et al.
Contraception|November 16, 2004
Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 productEliana Amaral, Antero Perdigão, Maria Helena Souza, et al.
Menopause (New York, N.Y.)|August 25, 2023
A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
Menopause (New York, N.Y.)|June 20, 2023
A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
Contraception|April 22, 2006
Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 productEliana Amaral, Antero Perdigao, Maria Helena Souza, et al.
Sexually Transmitted Diseases|November 30, 2012
A quantitative glycogen assay to verify use of self-administered vaginal swabsDeborah J Anderson, Joseph A Politch, Jeffrey Pudney, et al.
Journal of Lower Genital Tract Disease|September 30, 2008
Colposcopically observed vascular changes in the cervix in relation to the hormonal levels and menstrual cycleSmita N Joshi, Soma Das, Madhuri Thakar, et al.
Contraception|May 15, 2008
Consistent use of a combination product versus a single product in a safety trial of the diaphragm and microbicide in Harare, ZimbabweAriane van der Straten, Jie Moore, Sue Napierala, et al.
Pageof 5